ThursdaySep 07, 2023 3:26 pm

BC Study Uncovers Cause of Four Major Pediatric Allergies

New research by scientists from the University of British Columbia (UBC) and British Columbia Children’s Hospital has revealed that four major childhood allergies may arise from a common factor. The Centers for Disease Control and Prevention (CDC) estimates that close to one in five children suffer from seasonal allergies, with 10.8% living with eczema and 5%–8% suffering from food allergies. These allergies typically occur due to factors such as outdoor and indoor triggers, irritants including perfumes and cigarette smoke, and consuming certain foods. Since each type of allergy tends to arise from different factors, developing treatment or therapy that can…

Continue Reading

ThursdaySep 07, 2023 9:30 am

The Strategic Brilliance of Acquiring High Times IP, Including Existing Licensing Agreements and Royalty Streams in All-Stock Transaction

Lucy Scientific Beats MindMed and Seelos Therapeutics to the Punch Lucy Scientific Discovery (NASDAQ: LSDI) (“Lucy” or the “Company), a Nasdaq-listed company with holdings and operations in a variety of psychotropic businesses, just announced the acquisition of the Intellectual Property of High Times, its Licensing Agreements and Royalty Streams in all-stock transaction. This was a brilliant strategic business move. With first movers in the “Mind Science” space like MindMed (NASDAQ: MNMD) and Seelos Therapeutics (NASDAQ: SEEL) realizing than 80% and 40% year-to-date gains respectively, today’s acquisition by Lucy delivers immediate revenue, an expanded product line, a proven and highly influential…

Continue Reading

WednesdaySep 06, 2023 9:46 am

Tracking Off-Label Cancer Treatment Could Ease Future Trials, Remedies

French researchers have discovered that tracking the use of off-label and compassionate cancer treatments could aid in the development and future use of anticancer therapies. The scientists collected data from qualifying patients aged 25 years old and younger who received cancer treatment at French pediatric cancer centers from March 2020 to June 2022. Analysis of this data allowed the research team to spot severe adverse drug reactions (ADRs) and determine how minors plus young adults responded to cancer treatments. Scientists across the globe are constantly working to develop new and innovative cancer therapies for minors as well as young adults,…

Continue Reading

TuesdaySep 05, 2023 12:16 pm

Policies Encouraging High-Volume Facilities Disadvantage Oncology Patients in Rural Areas

A new analysis published in the “JCO Oncology Practice” journal has revealed that policies encouraging high-volume medical facilities may be harming cancer patients living in rural areas. Health policy researchers at the University of Pittsburg School of Public Health discovered that cancer patients in rural Pennsylvania counties seem to be choosing to go to lower-volume health facilities closer to their homes even when they know higher-volume facilities may provide better outcomes. Rural areas often suffer from shortages of critical skills as most skilled professionals opt to move to urban areas for better pay. Rural America has a major shortage of…

Continue Reading

TuesdaySep 05, 2023 9:45 am

Genprex Inc. (NASDAQ: GNPX) Obtains New License for Novel Diabetes Gene Therapy Pipeline

U.S.-based gene therapy developer Genprex, Inc. is developing new therapies for fighting cancer tumors and diabetes The company’s gene therapies for battling types 1 and 2 diabetes use a simple endoscopic procedure to introduce select insulin-boosting genes directly to the pancreas to combat insulin decline factors in the body The company is working with research collaborators at the University of Pittsburgh (Pitt) and recently announced a new license agreement in relation to a gene therapy for both Type 1 and Type 2 diabetes The company’s novel infusion process using related gene therapy has shown statistically significant results in preclinical testing…

Continue Reading

FridaySep 01, 2023 1:05 pm

Bloomreach Unveils Conversational AI Tool for Online Shoppers

Marketing automation and software company Bloomreach has unveiled a conversational artificial intelligence (AI) tool to help online shoppers as they navigate e-commerce stores. Called Bloomreach Clarity, the new AI tool is powered by large language models and generative AI, a type of AI with the ability to produce all types of content including texts, images and video. The tool will help virtual stores provide human-like and personalized product information from their favorite companies and brands. It will also allow businesses to connect conversations with the AI model to specific product catalogs and integrate conversations from different communication channels. Machine learning…

Continue Reading

ThursdayAug 31, 2023 1:51 pm

Malaria Case Prompts Army to Ask Infectious Disease Experts to Analyze Mosquitoes

A group of infectious disease experts from several American Army institutions has been deployed to analyze mosquitoes after Maryland recently confirmed its first nontravel-connected malaria case in more than 40 years. Experts from the Walter Reed Army Institute of Research (WRAIR), the Smithsonian Institution and the U.S. Army’s First Area Medical Laboratory have teamed up to understand the recent case and combat malaria’s potential reemergence within the U.S. Scientists from the Aberdeen Proving Ground-stationed First Area Medical Laboratory will be deployed to the 44th Medical Brigade in Fort Liberty, North Carolina, and the 20th Chemical, Biological, Radiological, Nuclear, Explosives (CBRNE)…

Continue Reading

WednesdayAug 30, 2023 1:47 pm

UC San Diego Researchers Suggest Stem Cell Transplantation Could Treat Alzheimer’s

Ongoing research into a potential cure for Alzheimer’s disease has revealed that stem cell transplantation may be the key to treating the debilitating mental disease. Ongoing research at the University of California San Diego has pointed to stem cell transplants as a promising alternative treatment for the mental condition. Alzheimer’s disease affects parts of the brain that are involved in language, thought and memory, causing a steady decline in memory and cognitive abilities that eventually robs patients of their ability to take part in their day-to-day lives or even hold meaningful conversations. There are no existing cures for the neurodegenerative…

Continue Reading

WednesdayAug 30, 2023 9:45 am

Genprex Inc. (NASDAQ: GNPX) Celebrates Receipt of Orphan Drug Designation, Third Fast Track Designation Amid Preparations for Planned Acclaim-3 Clinical Trial

Genprex recently received orphan drug designation for its lead drug candidate REQORSA(R) Immunogene Therapy (quratusugene ozeplasmid) for the treatment of small cell lung cancer (“SCLC”) The company also celebrated receipt of its third Fast Track Designation (“FTD”), granted by the FDA, this time for REQORSA Immunogene Therapy, in combination with Tecentriq in patients with extensive stage small cell lung cancer (“ES-SCLC”) The orphan drug designation (“ODD”) in combination with the FTD is an indication of the great need for better treatment options for patients with ES-SCLC, and non-small cell lung cancer (“NSCLC”), according to Genprex President, Chairman, and CEO Rodney…

Continue Reading

TuesdayAug 29, 2023 1:01 pm

AI Helps Forecast Brain Tumor Outcomes

A team of researchers, including scientists from Stanford Medicine, has created an artificial intelligence (AI) model capable of forecasting brain tumor outcomes by examining stained images of a type of brain cancer called glioblastoma.  The researchers published a paper describing how the AI model could help physicians identify cellular markers for more aggressive tumors in patients before marking them for expedited follow-ups. Brain cancers tend to have poor outcomes because their proximity to important brain tissue makes them incredibly hard to treat via conventional methods such as surgery and radiation without harming healthy tissue. The blood-brain barrier, which is a…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000